Selank

Overview

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a stabilized analog of tuftsin, an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of immunoglobulin G. Selank has been studied primarily for anxiolytic (anti-anxiety), nootropic (cognitive), and immunomodulatory properties.

The overwhelming majority of the published evidence on Selank comes from Russian research groups, with relatively little independent replication in large Western randomized controlled trials. Selank is sometimes grouped with Semax, another Russian-developed neuropeptide, in discussions of peptide nootropics.

Chemistry and structure

Selank is built from the tuftsin sequence (Thr-Lys-Pro-Arg) extended at the C-terminus with a Pro-Gly-Pro motif intended to slow enzymatic degradation.

The added Pro-Gly-Pro tail is reported to confer greater resistance to amino- and carboxypeptidases than native tuftsin, which is rapidly degraded in plasma. Despite this, the parent peptide and Selank are both short-lived in blood; the measurable plasma presence is on the order of minutes, while reported behavioral and biochemical effects are described as outlasting it. The mechanistic explanation for this gap (active fragments, receptor-mediated effects, or downstream signaling) is not firmly established.

Mechanism of action

Selank's mechanism is described as multi-target rather than acting on a single receptor. The proposed mechanisms below are drawn largely from animal and cell-based studies; they are hypotheses supported to varying degrees rather than settled facts.

• GABAergic modulation. Selank has been reported to influence the GABA system, including allosteric-type effects and changes in the expression of GABAergic neurotransmission genes in rat frontal cortex, where its effects partially mirrored those of GABA itself (Volkova et al., 2016).
• Enkephalin metabolism. Selank is reported to inhibit enkephalin-degrading enzymes, raising levels of endogenous enkephalins. In the Zozulya clinical study, leu-enkephalin levels rose during Selank treatment and correlated with anxiety improvement.
• Monoaminergic effects. Studies report effects on serotonin and dopamine systems, including altered serotonin metabolism.
• BDNF and neuroplasticity. Selank has been reported to alter brain-derived neurotrophic factor (BDNF) content in the hippocampus and frontal cortex in rats, including in models of ethanol exposure (Kolik et al., 2019).
• Immunomodulation. Reflecting its tuftsin origin, Selank is reported to influence cytokine expression (for example interleukin-6) and T-helper cell cytokine balance.

Research and evidence

What did the human studies find?

The 2008 abstract describes 62 patients with anxiety or neurasthenia and reports similar anxiety relief with Selank and medazepam. This does not establish equivalence. A manufacturer-hosted reproduction gives different treatment-group sizes from the index; no adverse-event rate is calculated from that copy. 2008 (opens in a new tab).

In 2014, an open study with reported randomization compared Selank and phenazepam in 30 patients per group. At day 14, 5/30 versus 7/30 met the response criterion; at day 21, the figures were 17/30 versus 9/30 (p=0.037). Timing changes the interpretation. Allocation methods and attrition are insufficiently described. Source (opens in a new tab). Study card.

In 2015, 30 patients received phenazepam and 40 received phenazepam plus Selank. The day-14 response difference, 23% versus 40%, was not statistically significant (p=0.14). Earlier effects on some measures and fewer adverse effects were reported, but task speed declined in both groups. The 20 patients continuing Selank after day 14 must be distinguished from those stopping treatment. Source (opens in a new tab). Study card.

Both later studies report Peptogen support. Identical values in several control-group rows raise a possible participant-overlap question; they do not prove overlap. These reports should not be pooled as independent confirmations until recruitment is clarified.

Animal and laboratory evidence

The preclinical literature is broader and more mechanistic:

• Stress and anxiety models. Selank and related tuftsin-family peptides have shown anti-stress and "positive emotional" effects in animal conflict and stress paradigms (Kozlovskaya et al., 2003).
• Combination with benzodiazepines. In a chronic mild stress model, Selank reduced anxiety on its own and, combined with diazepam, returned anxiety indicators toward pre-stress baseline (Kasian et al., 2017).
• Gene expression. Selank altered expression of neurotransmission-related genes in rat frontal cortex (Volkova et al., 2016) and modified cellular responses to GABA and olanzapine in IMR-32 cells (Filatova et al., 2017).
• Neuroprotection / BDNF. Selank influenced BDNF content and reduced ethanol-associated memory impairment in rats (Kolik et al., 2019).
• Withdrawal models. Selank attenuated aversive signs of naloxone-precipitated morphine withdrawal in rats, with effects compared to diazepam (Konstantinopolsky et al., 2022).

Clinical and regulatory status

Selank's regulatory approval is essentially confined to Russia (and reportedly Ukraine). It has no marketing authorization in the United States or the European Union, and it has not undergone the large multi-center trials that Western regulators typically require. Where Selank appears outside Russia, it is generally as an unapproved research compound rather than an authorized medicine.

Russian research & registry

Selank's regulatory standing is verifiable in the primary register; its clinical evidence, by contrast, is small, Russian-language, and not broadly replicated.

• Registry-verified. Selank is registered in the Russian State Register of Medicines (ГРЛС) under registration number LRS-003338/09 (ЛРС-003338/09), marketed by Peptogen as 0.15% nasal drops; the registered composition is the heptapeptide Thr-Lys-Pro-Arg- Pro-Gly-Pro diacetate (1.5 mg/mL), registered as an anxiolytic with reported antidepressant and anti-asthenic action. This is a regulatory fact — a Russian approval under a different evidentiary standard — and is not an efficacy confirmation by the FDA or EMA.
• Primary efficacy evidence is thin. The most-cited clinical work comes from Russian research groups and compares Selank with a benzodiazepine in generalized anxiety; the trials are small, mostly open or actively-controlled rather than large placebo-controlled RCTs, and have not been independently replicated in Western settings. Much of the supporting literature is Russian-language and not indexed in the English databases most sites rely on — a limit of reach, not proof of absence, but also not a substitute for the larger blinded trials Selank has never had.

The registry fact is firm; the efficacy remains preliminary and Russian-weighted, and retrievability is not the same as high-quality evidence.

What adverse events were reported?

In the 2014 Selank-only group (30 patients), day-14 events were reported as follows. Percentages are rounded source values, not established population risks or proof of causation.

Nasal dryness was reported in 7% at day 21, after treatment ended, versus 0% at day 14. A separate table entry of 1% in a group of 30 is unresolved and is not used for risk estimation. Combination-treatment events cannot be attributed to Selank alone. Rare events, long-term safety and interactions remain insufficiently characterized. Source (opens in a new tab).

Legal status

Globally, Selank is most often described as unscheduled: it is not a controlled substance in most jurisdictions. But "unscheduled" is not the same as "approved" or "legal to sell as a medicine." In the United States, Selank is not an FDA-approved drug, is not a recognized dietary ingredient, and is typically sold only labeled "for research use only," which does not authorize human consumption. Legal treatment varies by country and can change; readers should not infer that availability implies regulatory endorsement.

How it compares

Selank is the anxiolytic counterpart to Semax: the two are frequently discussed together as Russian-developed neuropeptides that share a Pro-Gly-Pro stabilising tail and a similar regulatory position (registered in Russia, not FDA/EMA-approved). Selank is studied chiefly for anxiety, Semax for cognition and neuroprotection. As with Semax, most evidence comes from Russian research groups and lacks broad independent replication — the main caveat when comparing either to better-studied options. See the Cognition, mood & sleep overview.

Common misconceptions

• "Selank is FDA-approved / a proven anxiety medicine." It is not approved by the FDA or EMA. Its approval is essentially limited to Russia.
• "It's as proven as a benzodiazepine." Small Russian studies compared it favorably to benzodiazepines, but the evidence base is far smaller and less independently replicated than that of approved anxiolytics.
• "It's just a GABA drug." Its proposed mechanism is multi-target (enkephalin, monoamine, BDNF, immune, and GABAergic effects), and the pure-GABA framing oversimplifies inconsistent findings.
• "Short plasma half-life means it doesn't work." Reported effects are described as outlasting plasma presence, though the mechanism for this is not firmly established.
• "Selank and Semax are interchangeable." Both are Russian neuropeptides, but they have different sequences, parent molecules, and primary research emphases.